CNBX · CNBX Pharmaceuticals Inc.
$0.00
+0.00 (+0.00%)
At close · Oct 22
Return incl. dividend (before tax)
Going-concern doubt
— flagged Jun 24, 2026
Substantial doubt about the company's ability to continue as a going concern.
“While the Company has incurred a net loss of $311,982 for the nine months ended May 31, 2026, it has incurred cumulative losses since inception of $25,580,358. These conditions raise substantial doubt about the ability of the Company to continue as a going concern. The ability of the Company to continue as a going concern is dependent upon its abilities to generate revenues, to continue to raise investment capital, and develop and implement its business plan. No assurance can be given that the Company will be successful in these efforts.”View the 10-Q filed Jun 24, 2026
Market Cap
$160,576
Shares
1.61B
Volume · Oct 22
70.04M
Avg daily vol (3M)
5.6M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.00
Open$0.00
Day$0.00–0.00
52W close$0.00–0.00
Avg vol 30d8.5M
Short int70K · 0.0% float · 1.0d
Short vol51%
DataJan 2020–Oct 2026
Filing10-Q · Jun 24
Up next
filed Jun 24, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$0
Trailing 12 months
Net income (TTM)
−$462,091
Trailing 12 months
Revenue growth YoY
-100.0%
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
0.1
Trailing earnings · reciprocal yield 1,000.0%
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
−$110,513
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+2,995.5%
Year over year · more shares
Price change (1Y)
-66.7%
Trailing year
Short interest
0.0%
Latest settlement · 1.0 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
High
Market backdrop
VIX 19 · elevated
Equity put/call 0.69
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−50%
below
Price vs 50-day avg
0%
above
RSI (14)
45
neutral
MACD trend
Positive
52-week position
0%
near low
Momentum
relative strength
1-month return
−50%
trailing
6-month return
0%
trailing
YTD return
−75%
this year
Relative strength
−6%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow
Flat
0% holders QoQ
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.00% of float · ▼ -30.0% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
1 holders — near 3-yr low, contrarian setup
Squeeze score
24
low risk · 0–100
Fundamentals
Revenue growth
−100%
Y/Y
EPS growth
+100%
Y/Y
Quant / Vol
risk profile
Volatility
572%
annualized · 1-yr
Max drawdown
−86%
past year
ATR
0.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−50%
Bearish
Price vs 50-day avg
0%
Neutral
RSI (14)
45
Neutral
MACD trend
Positive
Bullish
52-week position
0%
Bearish
Market signals — smart money & positioning
Bullish · 1 of 6
Trend (MA cross)
No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow
Flat
0% holders QoQ
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.00% of float · ▼ -30.0% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
1 holders — near 3-yr low, contrarian setup
Price context
position in its 52-week range
Range low $0
Now $0 · 0%
Range high $0
vs 200-day avg -50%
vs 50-day avg +0%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
KPI extraction has been attempted, but no publishable series is available from the examined filings. This is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CNBX
this stock
CNBX Pharmaceuticals Inc.
|
$160,576 | -75.0% | -100.0% | — | 0.0% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$136.14B | +18.0% | +46.2% | 31.3 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$82.95B | +6.1% | +20.8% | 20.0 | 2.1% |
|
MRNA
Moderna, Inc.
|
$80.90B | +587.1% | +4.3% | — | 7.7% |
|
CSLLY
Csl Ltd
|
$65.88B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Institutional Holders
Holders
1
- % held
- 0.0%
- Net QoQ
- 0 sh
- Top holder
- Archer Investment Corp
Held
Float
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CNBX | +0.0% | -50.0% | +0.0% | +0.0% | -75.0% |
| SPY | -1.0% | -0.4% | +6.0% | +0.2% | +12.0% |
| vs SPY | +1.0% | -49.6% | -6.0% | -0.2% | -87.0% |